Close Menu
Advertisement
Subscribe
[the_ad id="32629"]
Acute Lymphoblastic Leukemia

Addressing Unmet Need in ccRCC Through Targeted CXCR4 Blockade

Editor By No Comments1 Min Read

Paula Ragan, CEO, X4 Pharmaceuticals presents Addressing Unmet Need in ccRCC Through Targeted CXCR4 Blockade at the 2016 annual International Kidney Cancer Symposium.

Share.

Related Posts